Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 25 of 25 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
PTEN del	prostate cancer	not predictive	PI3K Inhibitor (Pan)	PX-866	Phase II	Actionable	In a Phase II trial, Sonolisib (PX-866) treatment resulted in stable disease as best response in 66.7% (2/3) of patients with recurrent or metastatic castration-resistant prostate cancer harboring homozygous PTEN deletion, while in PTEN wild-type patients resulted in a partial response in 14.3% (2/14) and stable disease in 28.6% (4/14) of patients (PMID: 31056399).	31056399
PTEN del	Advanced Solid Tumor	no benefit	Akt Inhibitor (Pan)	Atezolizumab + Ipatasertib	Phase II	Actionable	In a Phase II trial (CRAFT), treatment with Ipatasertib (GDC-0068) plus Tecentriq (atezolizumab) demonstrated safety but limited clinical benefit in advanced solid tumor patients harboring PI3K-AKT pathway mutations (n=13), including PTEN deletion/inactivating mutations or activating mutations in PIK3CA or AKT1, with a partial response in a breast cancer patient with AKT1 E17K and stable disease in a prostate cancer patient with PTEN loss (Ann Oncol (2023) 34 (suppl_2): S256-S257;NCT04551521).	detail...
PTEN del	glioblastoma	no benefit	PI3K Inhibitor (Pan)	Buparlisib + Capmatinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, combination of Buparlisib (BKM120) and Tabrecta (capmatinib) did not reach target exposure due to potential drug-drug interaction, and demonstrated minimal activity in patients with glioblastoma harboring PTEN alterations including deletion, mutation, or negative protein expression, therefore, Phase II of the trial was not initiated (PMID: 31776899; NCT01870726).	31776899
PTEN del	Advanced Solid Tumor	no benefit	PIK3CB inhibitor	GSK2636771	Phase I	Actionable	In a Phase I trial, patients with advanced solid tumors deficient in PTEN lacked benefit from GSK2636771 (PMID: 26117819).	26117819
PTEN del	prostate cancer	predicted - sensitive	PIK3CB inhibitor	AZD8186	Phase I	Actionable	In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including prostate cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).	detail...
PTEN del	Advanced Solid Tumor	sensitive		Onatasertib	Phase I	Actionable	In a Phase I trial, CC-223 demonstrated safety and preliminary efficacy in patients with solid tumors, including stable disease for greater than 110 days in 2 patients with PIK3CA mutation or PTEN deletion (PMID: 26177599).	26177599
PTEN del	lung non-small cell carcinoma	predicted - sensitive	PI3K Inhibitor (Pan)	PF-04691502	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-04691502 inhibited tumor growth in PTEN-deleted non-small cell lung cancer cell line xenograft models (PMID: 21750219).	21750219
PTEN del	prostate cancer	sensitive	PI3K Inhibitor (Pan)	VS-5584	Preclinical - Cell line xenograft	Actionable	In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a human prostate cancer cell line harboring a PTEN deletion in culture, and inhibited PI3K/MTOR signaling and tumor growth in xenograft models (PMID: 23270925).	23270925
PTEN del	stomach cancer	sensitive	PI3K Inhibitor (Pan)	MEN1611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MEN1611 (CH5132799) induced tumor regression in xenograft models of a human stomach cancer cell line with deletion of PTEN (PMID: 21558396).	21558396
PTEN del	prostate cancer	sensitive	PI3K Inhibitor (Pan)	MEN1611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MEN1611 (CH5132799) inhibited tumor growth in xenograft models of a human prostate cancer cell line with deletion of PTEN (PMID: 21558396).	21558396
PTEN del	prostate cancer	sensitive	Akt Inhibitor (Pan)	Ipatasertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, prostate cancer cell line xenograft models with PTEN deletion demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624).	24141624
PTEN del	prostate cancer	sensitive		Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Rubraca (rucaparib) induced senescence and increased radiosensitivity in PTEN null prostate cancer cells in culture (PMID: 23565244).	23565244
PTEN del	breast cancer	sensitive	PI3K Inhibitor (Pan)	CUDC-907	Preclinical - Cell culture	Actionable	In a preclinical study, CUDC-907 inhibited growth of breast cancer cells lines harboring Pten mutations and/or deletions (PMID: 22693356).	22693356
PTEN del	endometrial carcinoma	no benefit		Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) treatment did not significantly increase DNA damage or inhibit growth of an endometrial carcinoma cell line with PTEN knocked out via CRISPR/Cas9 system in culture (PMID: 28945226).	28945226
PTEN del	endometrial carcinoma	sensitive	PI3K Inhibitor (Pan)	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, Buparlisib (BKM120) inhibited Akt signaling, induced DNA damage, and inhibited the growth of an endometrial carcinoma cell line with PTEN knocked out via CRISPR/Cas9 system in culture (PMID: 28945226).	28945226
PTEN del	endometrial carcinoma	sensitive	PI3K Inhibitor (Pan)	Buparlisib + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Buparlisib (BKM120) and Lynparza (olaparib) resulted in enhanced DNA damage and growth inhibition in an endometrial carcinoma cell line with PTEN knocked out via CRISPR/Cas9 system in culture (PMID: 28945226).	28945226
PTEN del	breast cancer	sensitive	PI3K Inhibitor (Pan)	MEN1611	Preclinical - Cell culture	Actionable	In a preclinical study, MEN1611 (CH5132799) inhibited viability in breast cancer cell lines harboring a PTEN deletion in culture (PMID: 36913051).	36913051
PTEN del	prostate cancer	sensitive	PI3K Inhibitor (Pan)	Pictilisib + Vorinostat	Preclinical	Actionable	In a preclinical study, GDC-0941 and Zolinza (vorinostat) acted synergistically to inhibit growth of a human prostate cancer cell line harboring a PTEN deletion in culture (PMID: 9661880, PMID: 22693356).	22693356 9661880
PTEN del	prostate cancer	sensitive	PI3K Inhibitor (Pan)	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human prostate cancer cells harboring PTEN deletion in culture (PMID: 21325073, PMID: 14737113).	14737113 21325073
PTEN del	prostate cancer	sensitive	PIK3CB inhibitor	Alpelisib + AZD8186	Preclinical	Actionable	In a preclinical study, AZD8186 and Alpelisib (BYL719) combination treatment resulted in minor inhibition of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).	25544636
PTEN del	prostate cancer	sensitive	PIK3CB inhibitor	Alpelisib + AZD8186 + Enzalutamide	Preclinical	Actionable	In a preclinical study, AZD8186, Alpelisib (BYL719), and Xtandi (enzalutamide) combination treatment resulted in near-complete suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).	25544636
PTEN del	prostate cancer	sensitive	PIK3CB inhibitor	AZD8186 + Enzalutamide	Preclinical	Actionable	In a preclinical study, AZD8186 and Xtandi (enzalutamide) combination treatment resulted in suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).	25544636
PTEN del	urinary bladder cancer	sensitive		Metformin	Preclinical	Actionable	In a preclinical study, bladder cancer cells with PTEN deletion were sensitive to Glucophage (metformin) in culture, resulting in inhibition of cell growth (PMID: 26921394).	26921394
PTEN del	head and neck squamous cell carcinoma	resistant		Taselisib	Preclinical	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells homozygous for PTEN deletion were resistant to Taselisib (GDC-0032) in culture (PMID: 26589432).	26589432
PTEN del	prostate cancer	sensitive		RER	Preclinical	Actionable	In a preclinical study, RER treatment inhibited Tgf-beta and Akt pathways signaling, led to inhibition of tumor cell proliferation and tumorigenesis in a PTEN knock-out mouse model of prostate cancer (PMID: 27863384).	27863384

Showing 1 to 25 of 25 entries

Filter rows:

Profile Name	PTEN del
Gene Variant Detail	PTEN del (loss of function)
Relevant Treatment Approaches	Akt Inhibitor (Pan) Akt1 Inhibitor Akt2 Inhibitor PI3K Inhibitor (Pan) PIK3CB inhibitor

Molecular Profile Detail

Contact

Filtering

Sorting